K6/ODC transgenic mice as a sensitive model for carcinogen identification

Toxicology Letters

Volumn 116, Issue 1-2, 2000, Pages 27-35

  Chen, Yan ^a   Megosh, Louis C ^a,b   Gilmour, Susan K ^a   Sawicki, Janet A ^a   O'Brien, Thomas G ^a,b  

^a ODC Mouse Group Inc   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Carcinogenicity testing; Ornithine decarboxylase; Transgenic mouse model

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; BENZO[A]PYRENE; CACODYLIC ACID; CARCINOGEN; DIMETHYLBENZ[A]ANTHRACENE; EFLORNITHINE; GLYCIDOL; METHYLNITRONITROSOGUANIDINE; N BENZYL N METHYLNITROSAMINE; ORNITHINE DECARBOXYLASE; PHENACETIN; SULFAMETHOXAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR PROMOTION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENICITY TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; ORNITHINE DECARBOXYLASE; SKIN NEOPLASMS;

MURINAE; MUS MUSCULUS; RODENTIA;

EID: 0033934631     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(00)00196-X     Document Type: Article

References (33)

1. Auvinen M., Paasinen A., Anderson L.C., Holtta E. Ornithine decarboxylase activity is critical for cell transformation. Nature (Lond.). 360:1992;355-358.
2. Bollag W. Prophylaxis of chemically induced benign and malignant epithelial tumors by vitamin A acid (retinoic acid). Eur. J. Cancer. 8:1972;689-693.
3. Boutwell R.K. The functions and mechanisms of promoters of carcinogensis. CRC Crit. Rev. Toxicol. 2:1974;419-443.
4. Butcher J.R. Update on National Toxicology Program (NTP) assay with genetically altered or 'transgenic' mice. Environ. Health Perspect. 106:1998;619-621.
5. Clifford A., Morgan D., Yuspa S.H., Peralta Soler A., Gilmour S. Role of ornithine decarboxylase in epidermal carcinogenesis. Cancer Res. 55:1995;1680-1686.
6. Cotsarelis G., Sun T.T., Lavker R.M. Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell. 61:1990;1329-1337.
7. De Viries A, van Oostrom C.Th.M., Hofhuis F.M.A., Dortant P.M., Berg R.J.W., De Gruijl F.R., Wester P.W., Van Kreijl C.F., Capel P.J.A., Van Steeg H., Verbeek S.J. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature. 377:1995;169-173.
8. Eastin W. The U.S. National Toxicology Program evaluation of transgenic mice as predictive models for identifying carcinogens. Environ. Health Perspect. 106:1998;81-84.
9. Gilmour S.K., Aglow E., O'Brien T.G. Heterogeneity of ornithine decarboxylase expression in 12-O-tetradecanoylphorbol-13-acetate-treated mouse skin and in epidermal tumors. Carcinogenesis. 7:1986;943-947.
10. Gilmour S.K., Verma A.K., Madara T., O'Brien T.G. Regulation of ornithine decarboxylase gene expression in mouse epidemis and epidermal tumors during two-stage tumorigenesis. Cancer Res. 4:1987;1221-1225.
11. Goodman G., Wilson R. Predicting the carcinogenicity of chemicals in human from rodent bioassay data. Environ. Health Perspect. 94:1991;195-218.
12. Halmekyto M., Syrjanen J.J., Alhonen L. Enhanced papilloma formation in response to skin tumor promotion in transgenic mice overexpressing the human ornithine decarboxylase gene. Biophys. Res. Commun. 187:1992;493-497.
13. Haseman J.K., Hailey J.R. An update of the national toxicology program database on nasal carcinogens. Mutat. Res. 380:1997;3-11.
14. Hietala O., Dzubow L., Dlugosz A.A., Gilmour S.K., O'Brien T.G. Activation of human squamous cell carcinoma ornithine decarboxylase activity by guanosine triphosphate. Cancer Res. 48:1988;1252-1257.
15. Kitchin K.T., Brown J.L., Kulkarni A.P. Predicting rodent carcinogenicity by in vivo biochemical parameters. Environ. Carcinog. Ecotox. Rev. C12(1):1994;63-68.
16. Koza R.A., Megosh I.D., Palmieri M., O'Brien T.G. Constitutively elevated levels of ornithine and polyamines in mouse epidermal papilloma. Carcinogenesis. 12:1991;1619-1625.
17. Lavker R.M., Fryer E., Margolis-Fryer J., Ostad M., Cotsarelis G., Sun T.T. Cells in the bulge region of mouse hair follicle undergo transient proliferation during onset of anagen and response to physical and chemical stimuli. J. Invest. Dermatol. 98:1992;581.
18. Luk G.D., Baylin S.B. Ornithine decarboxylase as a biologic marker in familial colonic polyposis. N. Engl. J. Med. 311:1984;80-83.
19. McClellan R.O. Reducing uncertainty in risk assessment by using specific knowledge to replace default options. Drug Metab. Rev. 28:1996;149-179.
20. Megosh L., Gilmour S.K., Rosson D., Peralta Soler A., Blessing M., Sawicki J.A., O'Brien T.G. Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase. Cancer Res. 55:1995;4205-4209.
21. Miller S.J., Wei Z.G., Wilson C., Dzubow L., Sun T.T., Lavker R.M. Mouse skin is particularly susceptible to tumor initiation during early anagen of the hair cycle: possible involvement of hair follicle stem cells. J. Invest. Dermatol. 101:1993;591-594.
22. Moshier J., Dosescu J., Skunca M., Luk G. Transformation of NIH 3T3 cells by ornithine decarboxylase overexpression. Cancer Res. 53:1993;2618-2622.
23. O'Brien T.G., Simsiman R.C., Boutwell R.K. Induction of the polyamine biosynthetic enzymes in mouse epidermis by tumor promoting agents. Cancer Res. 35:1975;1662-1670.
24. O'Brien T.G., Megosh L.C., Gillard G., Soler A.P. Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res. 57:1997;2630-2637.
25. Shantz L.M., Pegg A.E. Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res. 54:1994;2313-2316.
26. Takigawa M., Verma A.K., Simsiman R.C., Boutwell R.K Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine biosynthesis by α-difluoromethylornithine. Cancer Res. 43:1983;3732-3738.
27. Tennant R.W. Evaluation and validation issues in the development of transgenic mouse carcinogenicity bioassays. Environ. Health Perspect. 106:1998;473-476.
28. Tennant R.W., French J.E., Spalding J.W. Identifying chemical carcinogens and assessing potential risk in short-term bioassay using transgenic mouse models. Environ. Health Perspect. 103:1995;942-950.
29. Tennant R.W., Spalding J.W., French T.E. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutation Res. 365:1996;119-127.
30. Tennant R.W., Stasiewicz S., Mennear L., French J.E., Spalding J.W. The use of short- and medium-term tests for carcinogens and data on genetic effects in carcinogenic hazard evaluation. McGregor D.B., Rice J.M., Venitt S. Genetically Altered Mouse Models for Identifying Carcinogens, IARC Scientific Publication No. 146. 1999;123-150 International Agency for Research on Cancer, Lyon.
31. Weeks C.E., Hermann A.L., Nelson F.R., Slaga T.S. α-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc. Natl. Acad. Sci. USA. 79:1982;6028-6032.
32. Yamamoto S., Hayashi Y., Mitsumori K., Nomura T. Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-Hras gene. Lab. Anim. Sci. 47:1997;121-126.
33. Yuspa S.H., Poirier M.C. Chemical carcinogenesis from animal models to molecular models in one decade. Adv. Cancer Res. 50:1988;25-70.